Skip to content

Company

A next-generationneurotoxin biotechnology company.

Object Pharma is developing differentiated botulinum neurotoxins designed to unlock new therapeutic possibilities — beginning with Major Depressive Disorder.

Who we are

Who we are

A specialized biotechnology company advancing botulinum neurotoxin science — an innovative, fully integrated biopharma company dedicated to the development of new therapies for the treatment of mental illness.

Why we exist

To explore innovative therapeutic approaches addressing significant unmet medical needs, with a central commitment to mental and brain health.

Our primary focus

Major Depressive Disorder, through the development of OP01 — NextGen, our lead investigational candidate.

Our broader scientific interests

Exploring the wider therapeutic potential of botulinum neurotoxins — a proven therapeutic class whose biology may extend further.

Company story

Founding

Founded on July 13, 2018, Object Pharma was established to develop novel neurotoxins as human therapeutics.

Metabiologics

The addition of Metabiologics brought specialized neurotoxin production expertise and research infrastructure into the Object ecosystem.

OP01

Object Pharma initiated development of OP01, its lead investigational neurotoxin candidate, initially for Major Depressive Disorder.

ObNowa Pharma

The establishment of ObNowa Pharma expanded Object Pharma's ecosystem into European pharmaceutical development and medical aesthetics.

The Ecosystem

Three organizations.
One connected capability.

Metabiologics

Madison, Wisconsin

Neurotoxin science & specialized capabilities

  • Serotypes A–G research materials
  • Production know-how
  • Scientific infrastructure
  • Institutional neurotoxin knowledge

Object Pharma

Aliso Viejo, California & Madison, Wisconsin

Neurotoxin innovation & therapeutic development

  • Mental & brain health mission
  • OP01 — NextGen — MDD
  • Differentiated neurotoxin candidates
  • Global opportunities

ObNowa Pharma

Warsaw, Poland

European development & commercialization

  • European clinical development
  • Regulatory strategy & partnering
  • Medical aesthetics — incl. licensed hair & eyebrow programs
  • Commercialization

The companies of the Object ecosystem operate distinct programs; not every program is shared between the three companies. ObNowa program details are described at a high level only.

Governance

Content Coming Soon

Our Purpose

Help people.Minimize suffering.Follow the science.

Science is the mechanism. Patients are the reason.